[Ip-health] Kymriah, the Novartis $475, 000 CAR T treatment, received 50 percent Orphan Drug tax credit on trials | Knowledge Ecology International

Jamie Love james.love at keionline.org
Thu Aug 31 10:25:01 PDT 2017


Missing in the reporting on the Novartis price for Kymriah, its new
$475,000 CAR T treatment, is that Novartis received an Orphan Drug
designation in February 3, 2015, and sequently received a tax credit
subsidy from the United States equal to 50 percent of the cost of
qualifying clinical trials.

>From the FDA database on Orphan Designations:


More information about the Ip-health mailing list